McKesson (MCK)
(Delayed Data from NYSE)
$525.28 USD
-0.66 (-0.13%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $525.55 +0.27 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$525.28 USD
-0.66 (-0.13%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $525.55 +0.27 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Zacks News
Manufacturing Data Improves, Bond Yields Stay Elevated
by Mark Vickery
We got some slightly better September Manufacturing numbers than expected from the final S&P PMI and ISM reports.
Why McKesson (MCK) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Take the Zacks Approach to Beat the Market: Shopify, Caterpillar, Amgen in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Veradigm's (MDRX) New Tie-Up to Boost Patients' Health Outcomes
by Zacks Equity Research
Veradigm's (MDRX) latest partnership is likely to promote value-based care initiatives for healthcare providers and the patients they serve.
4 Stocks That Stand Out on Attractive Interest Coverage Ratio
by Sumit Singh
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. MOD, SFM, MOH and MCK are sound enough to meet financial obligations.
Here's Why You Should Retain Ecolab (ECL) Stock for Now
by Zacks Equity Research
Ecolab's (ECL) strength in its business raises optimism about the stock.
Zacks.com featured highlights include Applied Materials, PulteGroup, Arcos Dorados Holdings, McKesson, and NetEase
by Zacks Equity Research
Applied Materials, PulteGroup, Arcos Dorados Holdings, McKesson, and NetEase are part of the Zacks Screen of the Week article.
3 Reasons to Hold Catalent (CTLT) Stock in Your Portfolio
by Zacks Equity Research
Catalent's (CTLT) product and service launches and a slew of strategic deals raise optimism about the stock.
DexCom (DXCM) Partners With RxFood for Automated Dietary Monitoring
by Zacks Equity Research
DexCom's (DXCM) CGM systems will make dietary assessment through AI-enabled RxFood app, which automatically interprets food images for calorie count in Canada.
Dive Into Dividends: Top 5 Bargain Growth Stocks to Buy
by Sweta Killa
Applied Materials (AMAT), PulteGroup (PHM), Arcos Dorados (ARCO), McKesson (MCK) and NetEase (NTES) could be compelling picks for investors in the current scenario.
Here's Why You Should Retain Inspire Medical (INSP) Stock Now
by Zacks Equity Research
Inspire Medical's (INSP) focus on R&D raises optimism about the stock.
NextGen (NXGN) Extends Agreement to Boost Athletico's Footprint
by Zacks Equity Research
NextGen's (NXGN) latest extended agreement is likely to reflect its solutions' potential to aid healthcare organizations at all stages of growth.
Reasons to Retain Patterson Companies (PDCO) in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.
HealthEquity (HQY) to Add Conduent's HSA Accounts in 2024
by Zacks Equity Research
HealthEquity (HQY) is set to receive the Conduent's HSA portfolio as a part of an agreement signed by the companies earlier this month. The deal is likely to boost HQY's business in 2024 and beyond.
QuidelOrtho's (QDEL) Rapid Antigen Test Gets CLIA Waiver
by Zacks Equity Research
QuidelOrtho's (QDEL) receipt of the FDA's CLIA waiver is expected to widen access to the rapid antigen test in any point-of-care setting equipped with Sofia 2 instruments.
3 Reasons to Hold HealthEquity (HQY) Stock in Your Portfolio
by Zacks Equity Research
HealthEquity's (HQY) strength in HSA raises optimism about the stock.
Is McKesson (MCK) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Reasons to Retain West Pharmaceutical (WST) in Your Portfolio
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
5 Low-Beta Stocks to Sail Through a Choppy Market
by Ritujay Ghosh
Market volatility will stay for a longer time. Invest in socks like American Water Works Company (AWK), PepsiCo (PEP), Vistra Corp. (VST), McKesson Corporation (MCK) and J&J Snack Foods (JJSF).
McKesson (MCK) Announces Availability of FDA-Cleared Drug for MF
by Zacks Equity Research
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for MF.
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how DaVita HealthCare (DVA) and McKesson (MCK) have performed compared to their sector so far this year.
3 Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.
The Zacks Analyst Blog Highlights Procter & Gamble, Amazon.com, Verizon Communications, McKesson Corporation and D.R. Horton
by Zacks Equity Research
Procter & Gamble, Amazon.com, Verizon Communications, McKesson Corporation and D.R. Horton are part of the Zacks top Analyst Blog.